PCSO-524® (Antinol®) Use in Persian Cat with Dynamic Hypertrophic Obstructive Cardiomyopathy (HOCM)
Authors:
Antinol® Case Study 2018 Content
3rd Winning Award
PCSO-524® (Antinol®) Use in Persian Cat with Dynamic Hypertrophic Obstructive Cardiomyopathy (HOCM)
Kanok Bamrungsri, DVM, Changwattana Animal Hospital
Honorable Committee
1) Associate Professsor, Dr.Rosama Pusoonthornthum, Veterinary Science, Chulalongkorn University
2) Assistant Professor Dr.Monchanok Vijarnsorn, Veterinary Medicine, Kasetsart University
3) Assistant Professor Dr.Walasinee Sakcamduang, Veterinary Science, Mahidol University
4) Assistant Professor Dr.Kumpanart Sundaravibhata, Veterinary Science, Chulalongkorn University
5) Dr. Chaiyot Tanrattana, Veterinary Science, Chulalongkorn University
6) Assistant Professor Dr.Tassanee Jaroensong, Veterinary Medicine, Kasetsart University
Abstract
A Persian cat aged 21 years was diagnosed with Dynamic Hypertrophic Obstructive Cardiomyopathy (HOCM) and treated with PCSO-524® (Antinol®) for 45 days.
The cat regained quality of life and daily activities such as grooming and walking, increased appetite, ingestion and weight gain after the treatment. Serum Amyloid A (SAA), which is an inflammatory marker in cats, was reduced down to normal after 15 days of PCSO-524® (Antinol®) administration.
Keywords: PCSO-524® (Antinol®) Dynamic Hypertrophic Obstructive Cardiomyopathy (HOCM)